locator iconlocator icon
All Labs
 
add to cart

Coombs Test - Indirect

500350
30% Coupon
4.1
NABL, CAP, ISO
ADD TO CART
Overview
Interpretations
FAQ's
Coombs Test - Indirect

Overview of Coombs Test - Indirect

What is Coombs Test - Indirect?

The Indirect Coombs Test, also called Indirect Antiglobulin Test (IAT) is a laboratory procedure performed to identify the presence or absence of antibodies in blood directed against antigens found on red blood cells to determine compatibility for blood transfusion, Rh incompatibility between pregnant woman and her child, and the possibility of hemolytic anemia occurring due to autoimmune disorder.

Sample Type

The sample type collected for Coombs Test - Indirect is: Blood

Preparation for Coombs Test - Indirect

  • No special preparation required

Why Get Tested for Coombs Test - Indirect?

The Indirect Coombs Test is performed:

·    When donating blood, tissue, organ, or bone marrow or while getting registered as a potential donor

·  Before receiving a blood transfusion or blood components transfusion to determine compatibility with donated blood

·    Before pregnancy and during pregnancy to determine the risk of incompatibility between the mother and fetus

·    To determine if hemolytic anemia is caused due to an autoimmune disorder



Understand more about Coombs Test - Indirect

The red blood cells have specific antigen markers present on their surface. These marker antigens are glycoproteins and help the body to recognize its own type of Red Blood Cells (RBCs). Antibodies are naturally produced against incompatible RBC antigens when there is exposure to incompatible red blood cells. Three commonest antigen markers found on RBCs are A, B, and Rh, and the presence or absence of these antigen markers is used to determine the blood group of a person.

Blood transfusion between incompatible blood types causes an antigen-antibody reaction which causes the RBCs to clump together (agglutination) and this results in their destruction. Hence blood groups of donor and recipient must match to ensure the success of the blood transfusion or organ transplant. Agglutination may also occur due to Rh incompatibility between Rh-negative pregnant woman (who is having Rh antibodies because of previous sensitization) and her Rh-positive child which may cause antibodies in the mother to cross the placenta and attack the RBCs of the foetus. In some autoimmune disorders, antibodies are produced against antigens on the body’s own RBCs. These antibodies may attack the ‘self’ RBCs and cause agglutination.

The Indirect Coombs Test is performed on the principle of the antigen-antibody reaction between incompatible blood groups. The collected blood specimen is treated with a large range of collected or synthetic human RBC antigens and observed under a microscope. If agglutination (clumping) of RBCs is seen upon treatment with a particular antigen, antibodies against that antigen are already present in the blood specimen. Antibodies against RBC antigens A and B occur naturally, while antibodies against other RBC antigens are produced upon exposure to the corresponding antigen. A similar test called the Direct Coombs Test is performed to detect the presence of antibodies (bound to RBCs) against the body’s own RBCs (autoimmune antibodies) that may be the cause of autoimmune hemolytic anemia.


What Results of Coombs Test - Indirect mean?

Interpretations

Agglutination: Positive result, antibodies present

No agglutination: Negative result, antibodies absent



Result

Interpretation

Negative

No antibodies detected

Equivocal

Positive in undiluted serum up to 1:16 titre

Positive

Positive in titre of 1:32 or above

Positive in increasing titre in subsequent tests


Antibodies are produced in blood upon exposure to incompatible antigens as during a blood transfusion. Antibodies produced in the first incompatible transfusion produce severe reactions upon subsequent transfusions of the same blood type.


Patient Concerns about Coombs Test - Indirect

Frequently Asked Questions about Coombs Test - Indirect

Q. How is this test performed?
This test is performed on a blood sample. A syringe with a fine needle attached is used to withdraw blood sample from a blood vessel in your arm generally from the inner side of the elbow area. The doctor, nurse or the phlebotomist will tie an elastic band around your arm which will help the blood vessels to swell with blood and hence makes it easier to withdraw blood. You may be asked to tightly clench your fist. Once the veins are clearly visible, the area is cleaned with an antiseptic solution and then the needle is inserted into the blood vessel to collect the sample. You may feel a tiny pinprick during the procedure. Blood sample once collected is then sent to the laboratory.
Q. Is there any risk associated with this test?
There is no risk associated with the test. However, as this test involves a needle prick to withdraw the blood sample, rarely, a patient may experience increased bleeding, hematoma (blood collection under the skin) formation, bruising or infection at the site of needle prick.
+ more

Provided By

NABL

CAP

ISO

With a decade of experience under its belt, Oncquest is known for its excellence in Clinical Diagnostics. From its first avatar as an R&D focused entity, Oncquest has evolved into a reference laboratory in the field of Oncology, and more recently into a multi-platform Pathology Services provider with a core focus in Molecular Pathology and Surgical Pathology Services. Its logistic capabilities and geographical spread makes Oncquest an ideal associate for clinical activities in India. Oncquest’s accredited quality systems ensure customer satisfaction through any of its customer-centric service offerings. Oncquest’s recent advances in the areas of Companion Diagnostics and Pharmacogenomics have also allowed for and encouraged greater penetration of Personalized Medicine into the Indian healthcare market, making it the future epicentre of the many technological advancements in healthcare, to come. Its close association with many Hospitals across India stands testament to the faith that Oncquest has instilled in the doctors and patients which avail of its services. Oncquest is fast becoming a cornerstone for a blooming healthcare industry. With over a decade of experience in the field of molecular diagnostics and pathology services, Oncquest Laboratories has earned its reputation of clinical excellence in the Indian market. Our advanced technologies and global quality systems have ensured that we stay ahead of the curve, and this has resulted in our association with some of the most advanced clinicians, hospitals and research organizations in the country. As India gets set for a clinical revolution, ushering in a trend of new healthcare services and products, Oncquest has defined its place as a partner of choice for those who bring value to our proud subcontinent. Our national reach and sizeable knowledge base allows us to be at the forefront of scientific advances, and an ideal partner for clinical activities. We strive to be connected with the best in the industry and we welcome partnership in ideas and technologies. For example, Oncquest’s early adoption and utilization of genetic sequencing technologies has resulted in many “first to market” assays, which have subsequently been adopted in several treatment and monitoring protocols. Innovation is an essential part of our DNA. We welcome challenges, and look forward to associating with you and your organizations to develop pioneering solutions and to tackle some of the most pressing issues faced in our world.

Available at Other Labs

VIEW ALL